Browse STRC

Summary
SymbolSTRC
Namestereocilin
Aliases DFNB16
Chromosomal Location15q15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell surface Cell projection, kinocilium Cell projection, stereocilium
Domain -
Function

Essential to the formation of horizontal top connectors between outer hair cell stereocilia.

> Gene Ontology
 
Biological Process GO:0002064 epithelial cell development
GO:0002065 columnar/cuboidal epithelial cell differentiation
GO:0002066 columnar/cuboidal epithelial cell development
GO:0002093 auditory receptor cell morphogenesis
GO:0007160 cell-matrix adhesion
GO:0007423 sensory organ development
GO:0007605 sensory perception of sound
GO:0008544 epidermis development
GO:0009581 detection of external stimulus
GO:0009582 detection of abiotic stimulus
GO:0009612 response to mechanical stimulus
GO:0009913 epidermal cell differentiation
GO:0031589 cell-substrate adhesion
GO:0035315 hair cell differentiation
GO:0042471 ear morphogenesis
GO:0042472 inner ear morphogenesis
GO:0042490 mechanoreceptor differentiation
GO:0042491 auditory receptor cell differentiation
GO:0043583 ear development
GO:0048562 embryonic organ morphogenesis
GO:0048568 embryonic organ development
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048839 inner ear development
GO:0050910 detection of mechanical stimulus involved in sensory perception of sound
GO:0050954 sensory perception of mechanical stimulus
GO:0050974 detection of mechanical stimulus involved in sensory perception
GO:0050982 detection of mechanical stimulus
GO:0060088 auditory receptor cell stereocilium organization
GO:0060113 inner ear receptor cell differentiation
GO:0060117 auditory receptor cell development
GO:0060119 inner ear receptor cell development
GO:0060122 inner ear receptor stereocilium organization
GO:0060563 neuroepithelial cell differentiation
GO:0090596 sensory organ morphogenesis
Molecular Function -
Cellular Component GO:0005929 cilium
GO:0031513 nonmotile primary cilium
GO:0032420 stereocilium
GO:0032421 stereocilium bundle
GO:0032426 stereocilium tip
GO:0060091 kinocilium
GO:0072372 primary cilium
GO:0098858 actin-based cell projection
GO:0098862 cluster of actin-based cell projections
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolSTRC
Namestereocilin
Aliases DFNB16
Chromosomal Location15q15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between STRC and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSTRC
Namestereocilin
Aliases DFNB16
Chromosomal Location15q15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of STRC in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSTRC
Namestereocilin
Aliases DFNB16
Chromosomal Location15q15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of STRC in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0590.898
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0480.98
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1890.931
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.6690.12
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.3980.0424
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1050.889
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1820.671
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.110.864
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0420.82
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of STRC in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.82.712.10.0439
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.83.411.40.0746
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.3014.30.238
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.112.5-1.41
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59022.2-22.20.505
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.57.15.41
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolSTRC
Namestereocilin
Aliases DFNB16
Chromosomal Location15q15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of STRC. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSTRC
Namestereocilin
Aliases DFNB16
Chromosomal Location15q15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of STRC. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by STRC.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSTRC
Namestereocilin
Aliases DFNB16
Chromosomal Location15q15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of STRC. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSTRC
Namestereocilin
Aliases DFNB16
Chromosomal Location15q15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of STRC expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSTRC
Namestereocilin
Aliases DFNB16
Chromosomal Location15q15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between STRC and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSTRC
Namestereocilin
Aliases DFNB16
Chromosomal Location15q15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting STRC collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.